Insider Selling: Galectin Therapeutics (NASDAQ:GALT) CFO Sells 20,354 Shares of Stock

by · The Cerbat Gem

Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) CFO Jack Callicutt sold 20,354 shares of the stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $3.67, for a total transaction of $74,699.18. Following the transaction, the chief financial officer owned 7,614 shares of the company’s stock, valued at approximately $27,943.38. The trade was a 72.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Galectin Therapeutics Stock Performance

NASDAQ GALT traded down $0.43 on Tuesday, hitting $3.45. 905,529 shares of the stock traded hands, compared to its average volume of 684,117. The business’s fifty day moving average is $5.34 and its two-hundred day moving average is $4.39. Galectin Therapeutics Inc. has a 12 month low of $1.07 and a 12 month high of $7.13. The firm has a market capitalization of $222.42 million, a price-to-earnings ratio of -5.85 and a beta of 1.03.

Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Analysts expect that Galectin Therapeutics Inc. will post -0.73 EPS for the current fiscal year.

Key Headlines Impacting Galectin Therapeutics

Here are the key news stories impacting Galectin Therapeutics this week:

  • Negative Sentiment: CEO Joel Lewis sold multiple blocks of stock (Jan. 2, Jan. 5 and Jan. 6), totaling 83, (serial sales of 18,571; 27,731; 37,698 shares) at average prices around $4.20–$3.58, reducing his stake by ~4% overall — signaling significant insider liquidity. CEO Joel Lewis Form 4
  • Negative Sentiment: CFO Jack W. Callicutt also executed staged sales (Jan. 2, Jan. 5 and Jan. 6), selling roughly 59, (13,914; 25,732; 20,354 shares) at avg. prices ~$4.20–$3.67, cutting his direct holdings by a large percentage — another material insider reduction. CFO Jack W. Callicutt Form 4
  • Negative Sentiment: Director/insider Khurram Jamil sold multiple tranches (Jan. 2, Jan. 5 and Jan. 6) totaling ~60,000+ shares across those dates at avg. prices from $4.20 to $3.65, substantially reducing his position — further insider selling pressure. Khurram Jamil Form 4
  • Negative Sentiment: Pomerantz LLP announced an investor investigation into Galectin on Jan. 6, which can increase legal risk and heighten short‑term selling pressure. Pomerantz Investor Alert

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. HC Wainwright upped their price target on shares of Galectin Therapeutics from $6.00 to $11.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Galectin Therapeutics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $11.00.

Check Out Our Latest Stock Report on GALT

Institutional Trading of Galectin Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of Galectin Therapeutics by 2.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,247,967 shares of the company’s stock worth $9,520,000 after acquiring an additional 63,419 shares during the last quarter. Osaic Holdings Inc. raised its position in Galectin Therapeutics by 3.4% during the second quarter. Osaic Holdings Inc. now owns 1,265,384 shares of the company’s stock valued at $2,670,000 after purchasing an additional 41,968 shares in the last quarter. Jane Street Group LLC bought a new stake in Galectin Therapeutics during the second quarter worth about $1,580,000. Wealthspire Advisors LLC boosted its holdings in shares of Galectin Therapeutics by 20.4% in the 2nd quarter. Wealthspire Advisors LLC now owns 479,518 shares of the company’s stock worth $1,012,000 after purchasing an additional 81,144 shares in the last quarter. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of Galectin Therapeutics by 8.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 423,235 shares of the company’s stock worth $516,000 after purchasing an additional 34,300 shares in the last quarter. Hedge funds and other institutional investors own 11.68% of the company’s stock.

About Galectin Therapeutics

(Get Free Report)

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.

Featured Articles